Background The economic costs associated with opioid misuse are immense. Effective interventions for opioid use disorders are available; however, given the scarce resources faced by substance use treatment providers and payers of all kinds, evidence of effectiveness is not always sufficient to encourage adoption of a given therapy-nor should it be. Economic evaluations can provide evidence that will help stakeholders efficiently allocate their resources. Objective The purpose of this study was to review the literature on economic evaluations of opioid use disorder interventions. Methods We performed a systematic review of the major electronic databases from inception until August 2015. A sensitive approach was used to ensure a comprehensive list of relevant articles. Given the quality of the existing reviews, we narrowed our search to studies published since 2007. The Drummond checklist was used to evaluate and categorize economic evaluation studies according to their quality. Results A total of 98 articles were identified as potentially relevant to the current study. Of these 98 articles, half (n = 49) were included in this study. Six of the included articles were reviews. The remaining 43 articles reported economic evaluation studies of interventions for opioid use disorders. In general, the evidence on methadone maintenance therapy (MMT) supports previous findings that MMT is an economically advantageous opioid use disorder therapy. The economic literature comparing MMT with other opioid use disorder pharmacotherapies is limited, as is the literature on other forms of therapy. Conclusion With the possible exception of MMT, additional high-quality economic evaluations are needed in order to assess the relative value of existing opioid use disorder interventions.
Introduction
Globally, opiates and opioids lead all other drugs in terms of the disease burden and drug-related deaths, with an estimated 33 million users [1] . Approximately half of the 33 million users suffer from an opioid use disorder; however, only about 10 % of those are receiving therapy [2] . The misuse of opioids has been linked to a host of physiological and sociological consequences [3] [4] [5] [6] [7] [8] [9] . Concomitantly, the economic costs associated with opioid misuse & Sean M. Murphy sean.murphy@wsu.edu are extremely high-over $92 billion (in 2014 US dollars [USD] ) annually in the USA alone [6, 7] . Birnbaum et al. [6] estimated that the societal costs of prescription opioid misuse were 46 % workplace related, 45 % healthcare related and 9 % criminal justice related. Effective interventions for opioid use disorders do exist. The two primary types of therapy are psychosocial and pharmacological. Reports from the World Health Organization (WHO) [10] and the National Quality Forum [11] have provided comprehensive overviews of the various types of therapies for opioid use disorders. Psychosocial therapies can be used by themselves or in combination with pharmacotherapy and are designed to alter the patient's motivation, such that it is no longer one of substance use; examples include cognitive behavioural therapies, relapse prevention, contingency management (CM) and motivational enhancement therapy. Pharmacotherapy options include opioid agonists, partial agonists and antagonists, as well as alpha-2-adrenergic agonists. Opioid agonist maintenance therapy, via the medications methadone (a full agonist) and buprenorphine (a partial agonist), is widely regarded as an effective-and possibly the most effective-form of therapy for opioid use disorders [12] [13] [14] [15] [16] . Methadone and buprenorphine can also be used to assist with short-term detoxification. Naloxone and naltrexone are opioid antagonists, implying that they block opioid receptors. These drugs have some advantages in that they are non-narcotic and non-addictive; however, because they block opioid receptors, they initiate withdrawal symptoms if taken by an individual who is physically dependent on opioids. Naloxone is typically combined with buprenorphine to reduce the likelihood of diversion, since it counteracts the effects of the opioid if the medication is administered parenterally. Naltrexone is available as a long-acting injectable and is primarily used to prevent relapse in opioid-dependent patients who have already been detoxified for 7-14 days [17, 18] .
Given the scarce resources faced by substance use treatment providers and payers of all kinds, evidence of effectiveness is not always sufficient to encourage adoption of a given therapy-nor should it be. Economic evaluations can provide evidence that will help stakeholders efficiently allocate their resources. The purpose of this study was to review the literature on economic evaluations of opioid use disorder interventions.
Review Methods
We performed a systematic review of the major electronic databases from inception until August 2015. The searched databases included PubMed/Medline, Cochrane Library, Cost-Effectiveness Analysis Registry, Web of Science, JSTOR, Science Direct and Google Scholar, UK National Health Service (NHS) Economic Evaluation Library Database, EconLit, PsycINFO, SciELO Citation Index, Social Science Citation Index and Derwent Innovations Index. A sensitive approach was used to ensure a comprehensive list of relevant articles. The searches included combinations of the following categories: (1) opioid or opiate, and dependence or disorder; (2) cost; (3) economic; and (4) . A number of recent systematic reviews of economic evaluations for various opioid use disorder interventions were identified [19] [20] [21] [22] [23] [24] [25] [26] . The most comprehensive review was performed by Doran [22] , who included studies up to 2007. Given the quality of the Doran review, which is discussed below, we narrowed our search to focus on studies published since 2007.
The first author (Dr. Murphy) performed the initial database searches to identify pertinent articles. Studies were included on the basis of a consensus between both authors following rigorous discussion. Studies were excluded if they were not an economic evaluation of an opioid use disorder intervention. For example, studies were excluded if they were editorials; if their emphasis was treatment of a disorder such as chronic pain or use of another substance; or if they focused solely on identifying the costs associated with opioid misuse, as opposed to potential cost offsets associated with various treatment alternatives, for example.
In order to build on the Doran [22] study, the Drummond checklist [27] was used to evaluate and categorize studies according to their quality. The Drummond checklist consists of ten primary questions intended to evaluate the quality and comprehensiveness of an economic evaluation. The ten questions focus on (1) the research question; (2) the description of the competing alternatives; (3) the establishment of the intervention's effectiveness; (4) the inclusion of all relevant costs and consequences; (5) the measurement of costs and consequences; (6) the valuation of costs and consequences; (7) whether costs and consequences were adjusted for differential timing; (8) whether an incremental analysis of costs and consequences was performed; (9) whether uncertainty in costs and consequences was taken into consideration; and (10) the quality of the discussion of the study results. Doran allocated a point to each question on the checklist and scored the reviewed studies accordingly, categorizing them as follows: poor quality (1-3 points); average quality (4-7 points); and good quality (8-10 points) . We too used this ranking system, which was applied to all studies, with the exception of review studies.
Results
A total of 98 articles were identified as potentially relevant to the current study. Of these 98 articles, half (n = 49) were included in this review (see Fig. 1 ). Twenty articles were excluded because they did not focus on opioid use disorders (e.g. they focused on long-term opioid therapy or abuse deterrent opioids) or they did not focus on the treatment of opioid use disorders as an outcome; 13 were excluded for not containing sufficient information on costs or other pertinent economic variables; eight were excluded because they focused solely on identifying the costs of opioid misuse or of providing a service; five were excluded for being editorial in nature; and three were excluded because they were poster abstracts published in conference proceedings.
Review Articles
Six of the articles included in the study were reviews. As mentioned above, Doran [22] performed a systematic review of studies published prior to 2007 that performed economic evaluations of opioid use disorder interventions. Doran concluded that, while the effectiveness of interventions for opioid use disorders (both pharmacological and behavioural) has been well established, information on the economic value of the said interventions was limited. On the basis of the author's assessment via the Drummond checklist [27] , the studies that were reviewed were of decent quality but fell short in a number of areas. According to Doran, there were too few well-designed cost-effectiveness analyses, particularly analyses by important subgroups, such as primary care and criminal justice settings, adolescents and pregnant women. Other shortcomings included (1) a lack of detailed evaluations on psychosocial interventions; (2) limits on the range of costs and consequences (e.g. inclusion of indirect costs such as productivity loss or cost offsets associated with reduced criminal activity); and (3) limited use of outcomes that capture a wider range of consequences associated with opioid use disorders (e.g. quality-adjusted life-years [QALYs] With regard to cost-benefit analyses of maintenance therapies, all of the studies reviewed by Doran demonstrated that the benefits outweighed the costs. In terms of the detoxification studies that were reviewed, Doran found that buprenorphine in an outpatient setting was one of the most cost-effective procedures and, again, found limited evidence that adding psychosocial support to pharmacotherapy improves outcomes. Five other review studies were identified. Each contained at least one study that met the inclusion criteria for our review and is therefore discussed below. Hartung et al. [24] conducted a meta-analysis of extended-release naltrexone studies that evaluated economic and healthcare utilization outcomes among individuals with opioid or alcohol use disorders. The only opioid study to meet the inclusion criteria for this paper was performed by Baser et al. [28] . Gastfriend [23] reviewed alcohol-and opioid use disorder pharmacotherapy studies to establish a pharmaceutical industry perspective on the economics of these treatments. Four articles relevant to this study were included [28] [29] [30] [31] . The Canadian Agency for Drugs and Technologies in Health [20] performed a review of the literature pertaining to the clinical and cost effectiveness of BMT, relative to MMT, for treatment of opioid use disorders. Only one study meeting the criteria for this review was included [32] . Shearer et al. [26] conducted a systematic review of CM economic evaluations. Three of the studies identified by the authors targeted opioid use as one of the clinical outcomes, two of which met the inclusion criteria for this study [33, 34] . Finally, Shanahan and Mattick [35] reviewed economic evaluations pertaining to pharmacotherapies for opioid use disorders. Four studies met our inclusion criteria [19, 21, 22, 36] .
Cost and Utilization
Thirty percent (n = 13) of the economic evaluation articles included in this paper focused primarily on comparing the levels of healthcare resource utilization and costs associated with different treatment modalities for opioid use disorders. Details on these papers and their Drummond checklist scores [27] are presented in Tables 1 and 2 , respectively.
Multiple Medications
Baser et al. [28] performed a retrospective cohort analysis of patients who were beneficiaries of a large, multistate, US commercial healthcare insurer and had an opioid use disorder. Beneficiaries who received one of the FDA-approved pharmacotherapies for opioid use disorders were compared with those who did not. On average, patients who received some type of pharmacotherapy utilized fewer healthcare resources and had lower total healthcare costs 6 months after treatment initiation than patients who did not receive pharmacotherapy [$10,192 versus $14,353 (in 2005 [$10,192 versus $14,353 (in -2009 ]. Comparisons between opioid use disorder pharmacotherapies revealed no significant differences with regard to detoxification/rehabilitation admissions, but there were significantly fewer other hospital admissions among patients receiving extended-release naltrexone. However, with regard to 6-month post-treatment costs, MMT patients were significantly more expensive than patients in the other three groups ($16,752 versus $10,049 for BMT, $8903 for oral naltrexone and $8582 for extended-release naltrexone).
Barnett [29] performed a retrospective cohort analysis of US Veterans Health Administration patients with an opioid use disorder. Patients who had a new BMT treatment episode were compared with those who had a new MMT treatment episode. BMT patients utilized fewer healthcare resources and had significantly lower predicted mean total healthcare costs than MMT patients [$11,597 versus $14,921 (in 2005 USD)] for the 6 months following treatment initiation. Additionally, the Cox proportional hazards regression indicated that new MMT episodes had a risk of ending that was approximately 1.6 times that of new BMT episodes.
Methadone Maintenance Therapy
McCarty et al. [37] conducted a retrospective cohort analysis of opioid-dependent members of a US commercial health plan. Beneficiaries receiving MMT were compared with those who did not receive MMT but had C2 outpatient visits for addiction treatment, and those who did not receive MMT and had \2 outpatient addiction treatment visits. Beneficiaries who received MMT had the lowest costs ($7163 [in 2004 USD]), followed by members who had C2 outpatient addiction treatment visits and no methadone ($14,157), and members who had B1 outpatient addiction treatment visit and no methadone ($18,694). The relatively low cost of members receiving MMT was due to fewer emergency department (ED) and primary care visits, fewer inpatient stays and less utilization of other non-addiction treatment services.
Gourevitch et al. [38] performed a retrospective cohort analysis of US Medicaid patients in an MMT programme. Patients who received long-term (at least 6-month) drug treatment with 'linked' on-site medical care were compared with those who received long-term drug treatment only and those who did not receive MMT. 'Linked' care was associated with more outpatient visits but fewer ED visits and hospitalizations, with no significant difference in total healthcare costs. Krebs et al. [39] completed a retrospective cohort analysis of illicit drug users in Canada who had accessed MMT and were involved in one of the following studies: the At-Risk Youth Study, the AIDS Care Cohort to evaluate Exposure to Survival Services or the Vancouver Injection Drug Users Study. The crime-related costs of individuals grouped into the following categories were compared: (1) MMT with high effectiveness; (2) MMT with low effectiveness; (3) opioid abstinence; or (4) relapse. From a societal perspective, which included criminal justice system and victimization costs, relative to relapse, the highest rates of avoided criminal costs were associated with abstinence [$6563 (in 2013 Canadian dollars (CAD))], followed closely by MMT with high effectiveness ($6298). MMT with low effectiveness was not associated with significant crime-related cost savings.
Buprenorphine-Naloxone Maintenance Therapy
Lynch et al. [40] conducted a retrospective cohort analysis of individuals with an opioid use disorder who belonged to one of two large integrated US commercial health systems. Eligible beneficiaries were categorized into one of the following groups: (1) BMT plus counselling; (2) counselling only; or (3) little to no addiction treatment. Beneficiaries receiving little to no treatment had significantly more primary care, other medical and ED visits than those receiving BMT plus counselling, who had had more inpatient detoxification visits but fewer primary care, other medical and mental health visits than the counselling-only group. The group receiving BMT plus counselling had significantly lower total healthcare costs than the group receiving little to no addiction treatment [$13,578 versus $31,035 (in 2008 USD)]; however, their total costs did not differ significantly from those of the counselling-only group ($17,017).
Tkacz et al. [41] performed a retrospective cohort analysis of patients who were beneficiaries of a large US commercial healthcare insurer and were prescribed buprenorphine-naloxone for an opioid use disorder. Beneficiaries who were adherent were compared with those who were not. Beneficiaries who were adherent incurred more pharmaceutical costs but utilized fewer high-cost services, resulting in significantly lower total healthcare charges ($28,458 versus $49,051 [in 2007-2012 USD]).
Martínez-Raga et al. [42] developed a budget impact model to estimate the healthcare costs of approving buprenorphine-naloxone as a method of treatment for opioid use disorders in Spain. In an updated model [43] , they estimated that the additional costs of buprenorphinenaloxone were small (€10.58 [in 2010 Euros (EUR)] per patient, or less), relative to a methadone-only scenario, with higher pharmaceutical costs being offset by lower logistic/distribution, production, delivery, supervision and monitoring costs.
Clay et al. [44] conducted a retrospective cohort analysis of opioid-dependent beneficiaries of a commercial US healthcare insurance company. Beneficiaries who had initiated treatment with buprenorphine-naloxone film were compared with those who had initiated treatment with the tablet version of the drug. Individuals treated with the film stayed with treatment longer and had significantly more outpatient visits, a lower likelihood of hospitalization and significantly lower (-27 %) total healthcare costs over the 12-month post-initiation study period.
Asche et al. [45] developed a Markov model to predict the relative costs of a cohort of patients with opioid use disorders being treated with either buprenorphine-naloxone film or a buprenorphine-naloxone tablet over 5 years. The authors found that although increased use of the film would result in increased outpatient care costs, it would generate savings overall because of reduced utilization of ED and inpatient services.
Khemiri et al. [46] conducted a retrospective cohort analysis of US beneficiaries who had an opioid use disorder and were enrolled in a commercial healthcare insurance plan or in Medicaid, and who had a new buprenorphinenaloxone prescription with at least one refill. Individuals receiving low-dose BMT were compared with those receiving high-dose BMT. High-dose BMT beneficiaries stayed in treatment longer and had a similar level of total direct healthcare costs to those receiving low-dose BMT, even though pharmacy costs were higher among the highdose group.
Kaur et al. [47] performed a retrospective pre-post analysis of beneficiaries who were continuously enrolled in a US managed care organization and had a new buprenorphine-naloxone prescription and at least one pharmacy claim for opioids in the previous 6 months. The researchers observed a significant decrease in the number of new opioid pharmacy claims. After accounting for the cost of the therapy (i.e. buprenorphine-naloxone), there was no significant difference in drug costs. Tables 3 and 4 contain information on cost-benefit and cost-effectiveness studies that focused on methadone maintenance as the therapy of interest. Details on the remaining economic evaluation studies are displayed in Tables 5 and 6 . 
Cost Effectiveness/Cost Benefit of Maintenance Treatments

Methadone Maintenance Therapy Alone Versus Methadone Maintenance Therapy with Counselling
Schwartz et al. [50] conducted a cost-benefit analysis of a US randomized controlled trial (RCT) testing the effectiveness of MMT with drug abuse counselling, relative to MMT without drug abuse counselling. The study participants were newly admitted heroin-dependent MMT patients. The analyses were conducted from the societal perspective. Although the cost per treatment episode was lower for MMT alone ($2052 versus $3411 [in 2010 USD]), the authors found no significant difference in the benefit-cost ratios between groups.
Methadone Maintenance Therapy Versus Residential Treatment
Basu et al. [51] performed a retrospective pre-post net monetary benefit analysis of patients in US residential and outpatient substance abuse treatment programmes. Individuals were receiving either outpatient MMT or were receiving residential short-term or long-term inpatient therapy. For patients aged C25 years, outpatient MMT produced a positive net monetary benefit for willingnessto-pay values above $60,000 (in 2001 USD) per robbery averted. The thresholds for short-term and long-term residential therapy were roughly $100,000 and $180,000, respectively. For patients aged \25 years, the threshold for all three modalities was approximately $40,000.
Methadone Maintenance Therapy Versus Usual Care Among HIV-Positive Drug Users
Using a retrospective cohort design, Xing et al. [52] conducted a CEA of MMT, relative to no MMT, among intravenous drug users (IDUs) seeking treatment in MMT clinics in China. The analyses were conducted from a provider perspective (i.e. government and public health Wammes et al. [53] conducted a CEA of MMT, relative to current practice, in a low-income setting in Indonesia over a 10-year time span. Data from the Asian epidemic model and the resource needs model were used to model IDUs, female sex workers and men having sex with men. The analyses were performed using a societal perspective. The findings indicated that MMT would cost approximately $7000 (in 2010 USD) per HIV infection averted.
Alistar et al. [54] conducted a CEA using a three-state dynamic compartmental model to assess the expansion of MMT, increased access to antiretroviral therapy (ART) or both over a 20-year time frame in Ukraine. A dynamic compartmental model is a type of mathematical model in which the study population is divided into compartments and the transition from one compartment to another is investigated. The three model compartments in this study were IDUs receiving MMT, IDUs actively injecting opioids and non-IDUs. The expansion of MMT alone was found to be the most cost-effective option, at $530 [in *2007 USD] per QALY gained, relative to current practice.
Tran and Nguyen [55] performed a retrospective cohort analysis of HIV-positive drug users who sought treatment at hospitals and health centres in Vietnam and responded to the HIV services users survey. Individuals with HIV or acquired immune deficiency syndrome (AIDS) who were being treated with MMT were compared with a propensitymatched group of non-MMT drug users with HIV/AIDS. The authors found that MMT was associated with significantly higher levels of health utility, lower levels of healthcare service utilization and fewer out-of-pocket healthcare costs. MMT patients paid approximately $232 (in 2012 USD) less in out-of-pocket costs annually than non-MMT patients.
Tran et al. [56] assessed the cost effectiveness of MMT versus no MMT in a retrospective cohort analysis of HIVpositive patients seeking treatment for an opioid use disorder at a stand-alone MMT clinic in Vietnam. The analyses were conducted from the perspective of health service providers over 9 months. The cost per QALY gained was $3550.5 (in 2009 USD), which was just over three times Vietnam's gross domestic product (GDP) per capita. The WHO's recommendations are that an intervention with an ICER less than the GDP per capita should be considered highly cost effective, those with an ICER between one and three times the GDP per capita should be considered cost effective and those with an ICER more than three times the GDP per capita be considered not cost effective [57] .
Tran et al. [58] used a decision analytic model to assess the cost effectiveness of integrating MMT and ART, relative to ART and MMT at separate sites and stand-alone ART, into the treatment of HIV-positive drug users in Vietnam. The analyses in this study were also conducted from the health provider's perspective. Relative to ART alone, the ICERs for providing ART and MMT at separate sites, and for integrating ART and MMT with direct administration, were $569.4 and $1227.8 (in 2009 USD), respectively, per QALY gained. According to the aforementioned WHO thresholds [57] , the separate-site ART and MMT model was highly cost effective and the direct administration model was cost effective.
Tran et al. [59] analysed the cost effectiveness and budgetary impact of MMT, relative to no MMT, using a decision analytic model. The study participants were HIVpositive IDUs seeking treatment for an opioid use disorder at a stand-alone MMT clinic in Vietnam. Again, the analyses were conducted from the health provider's perspective. The estimated ICER for MMT, relative to non-MMT, was $3324 (in 2009 USD) per HIV case averted and $964 per QALY gained. At 1.76 times the GDP per capita, this qualified MMT as cost effective. At the threshold of three times the GDP per capita, MMT would be considered cost effective 80 % of the time.
Methadone Maintenance Therapy Versus DeepBrain Simulation
Stephen et al. [60] constructed a decision analytic model to assess the cost effectiveness of deep-brain simulation (DBS), relative to MMT, from a US societal perspective. The study participants included individuals from 15 trials administering 6 months of MMT, and participants from 45 trials of DBS for movement disorders. The authors plotted the ICER (cost differential/QALY differential) against the probability of DBS success. MMT dominated DBS up to a success rate of 36.5 %, at which point, DBS became more effective. Using a willingness-to-pay threshold of $200,000 (in 2011 USD) per QALY gained, DBS would likely not be considered cost effective until a success rate of 50 % was achieved. The upper limit for the range of threshold values by which US society judges cost effectiveness has recently been estimated to be between $262,468 and $382,123 (in 2014 USD) per QALY gained [61] . At the traditional threshold of $50,000 per QALY gained, DBS would be cost effective at success rates over 57 %.
Methadone Maintenance Therapy or Buprenorphine-Naloxone Maintenance Therapy Versus Rehabilitation or Prison
Moore et al. [62] evaluated the cost effectiveness of pharmacotherapy maintenance (MMT or BMT), relative to residential rehabilitation and prison, using a retrospective cohort analysis of individuals seeking treatment for heroin dependence at a drug treatment agency in Australia. Data were obtained from the Australian Treatment Outcome Study, and analyses were conducted from a societal perspective. The authors predicted that if the post-programme abstinence rates were sustained for 2 years, the average cost per abstinent year would be $500 (in 2002 Australian dollars [AUD]) for pharmacotherapy maintenance, $11,000 for residential rehabilitation and $52,000 for prison.
Methadone
Maintenance Therapy or Buprenorphine-Naloxone Maintenance Therapy Versus Drug-Free Therapy
Clark et al. [63] performed a retrospective cohort analysis of Massachusetts Medicaid beneficiaries with an opioid use disorder. Beneficiaries who were receiving either BMT or MMT were compared with those receiving behavioural health treatment without opioid agonist therapy. Patients receiving BMT or MMT were approximately 50 % less likely to relapse and had mean monthly total healthcare costs that were $191 and $184 (in 2004-2010 USD) lower, respectively, than those receiving behavioural health therapy without opioid agonist therapy. Clark et al. [30] conducted a retrospective cohort analysis of Massachusetts Medicaid beneficiaries with an opioid use disorder. Beneficiaries who received either BMT or MMT were compared with those who received drug-free treatment or no treatment. The predicted mean monthly total Medicaid cost was significantly lower for BMT beneficiaries than for beneficiaries receiving drug-free or no treatment when short-term use episodes were included; the difference between BMT and MMT beneficiaries was not significant. Relapse rates were lowest among MMT beneficiaries, followed by BMT and drug-free-treatment beneficiaries. The number of deaths among BMT beneficiaries was not significantly different from the number among MMT beneficiaries but was significantly lower than the numbers among those in drug-free treatment and those receiving no treatment.
Methadone Maintenance Therapy Versus Injectable Heroin
Nosyk et al. [64] assessed the cost effectiveness of medically prescribed injectable heroin (i.e. diacetylmorphine), relative to MMT, using a decision analytic semi-Markov cohort model of participants in the North American Opiate Medication Initiative trial. The authors considered 1-, 5-, 10-year and lifetime horizons, using a Canadian societal perspective that incorporated costs to the healthcare and criminal justice systems. Diacetylmorphine dominated MMT at each time horizon, with many of the savings coming in the form of reduced criminal activity. The probabilistic sensitivity analysis indicated that diacetylmorphine would be considered cost effective at a willingness-to-pay threshold of $100,000 (in 2009 CAD) per QALY gained, with 95 % confidence. Byford et al. [65] evaluated the cost effectiveness of an RCT testing the effectiveness of supervised injectable heroin, relative to injectable and oral MMT. The study participants were chronic heroin users in the UK who were receiving oral MMT but continued to inject 'street' heroin on a regular basis. The analyses were conducted from the perspectives of society and the NHS. The authors found that oral MMT was dominated by both forms of injectable treatment from a societal perspective. Of the two forms of injectable treatment, injectable methadone appeared to be the more cost-effective option. Using the UK National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of £30,000 per QALY gained, injectable methadone had a slightly higher probability of being considered cost effective, relative to oral MMT, than injectable heroin (*75 versus *70 %). The authors noted, however, that many of the savings attributed to the injectable treatments were associated with the criminal justice system and that the two treatments became cost ineffective when an NHS perspective was considered.
Methadone Maintenance Therapy Versus
Buprenorphine-Naloxone Maintenance Therapy
Connock et al. [21] assessed the cost effectiveness of BMT, relative to MMT and no pharmacotherapy, using a decision analytic model of individuals in England with an opioid use disorder. The analyses were conducted from an NHS/personal social services (PSS) perspective. Both BMT and MMT were cost effective, relative to no pharmacotherapy, at £26,429 and £13,697 [in 2004 British pounds (GBP)], respectively, per QALY gained, while MMT dominated BMT. Jones et al. [31] performed a CEA of an RCT testing the effectiveness of office-based BMT, relative to clinic-and office-based MMT, in the treatment of opioid use disorders. The study participants were receiving outpatient MMT and had been stabilized for at least 1 year. The analyses were conducted from the perspectives of the provider and the patient. Clinic-based MMT was less expensive than officebased MMT or BMT for providers and patients. From the provider and patient perspectives, the costs (in 2006 USD) for each treatment modality were $147 and $239, respectively, for clinic-based MMT; $220 and $275, respectively, for office-based MMT; and $336 and $378, respectively, for office-based BMT. With regard to abstinence rates, the three treatments were statistically similar. The authors concluded that the cost of buprenorphine-naloxone was a major determinant of its total cost; therefore, they would expect their results to change following approval of a generic (generic approval of buprenorphine-naloxone occurred in 2013).
Maas et al. [66] evaluated the cost effectiveness of BMT, relative to MMT, among individuals with an opioid use disorder in the UK, using a non-equivalent group research design. The analyses were conducted from the provider perspective. BMT was dominated by MMT with regard to the programme's ability to retain patients for 6 months. However, with regard to the outcome of individuals who successfully detoxified, BMT generated a cost-effectiveness ratio of £903 (in 2010-2011 GBP) per individual who stopped using illicit opiates.
Geitona et al. [32] developed a budget impact model to evaluate the cost effectiveness of buprenorphine-naloxone, relative to buprenorphine monotherapy and MMT, among individuals with an opioid use disorder who were participating in opioid addiction therapy in Greece. The analyses were performed from the perspective of the Greek National Health System. The mean annual cost was lowest for buprenorphine-naloxone [€2875.6 versus €5626.4 for MMT and €6089.2 (in 2008 EUR) for buprenorphine monotherapy]. Buprenorphine-naloxone dominated MMT, given the lower cost, the increased percentage of participants completing therapy and the smaller number of avoided deaths.
Naltrexone Versus Methadone Maintenance
Therapy and Buprenorphine-Naloxone Maintenance Therapy
Jackson et al. [67] developed a Markov model to estimate the cost effectiveness of injectable extended-release naltrexone, relative to MMT and BMT, for US adult males receiving therapy for an opioid use disorder. From the perspective of state addiction treatment payers, the estimated cost-effectiveness ratio was $72 (in *2014 USD) per opioid-free day, relative to the next most effective treatment, MMT.
Buprenorphine-Naloxone Maintenance Therapy Versus No Treatment
Schackman et al. [68] developed a decision analytic model for a hypothetical cohort of clinically stable individuals with an opioid use disorder who had completed 6 months of BMT in a primary care setting, in order to assess its long-term cost effectiveness, relative to no treatment. From a societal perspective, BMT had a cost-effectiveness ratio of $35,000 (in 2010 USD) per QALY gained, at 24 months. The probabilistic sensitivity analysis indicated that the therapy had a 64 % chance of being considered cost effective at a willingness-to-pay threshold of $100,000 per QALY gained.
Buprenorphine-Naloxone Maintenance Therapy Versus Detoxification
Polsky et al. [69] analysed the cost effectiveness of BMT, relative to detoxification, in a 12-week clinical trial of US adolescents (15-21 years of age) with an opioid use disorder. The analyses were conducted from the perspectives of the payer, the provider and society. From the perspective of the payer, the therapy produced a cost-effectiveness ratio of $1376 (in 2006 USD) per QALY gained, with an 86 % chance of being considered cost effective at a willingnessto-pay threshold of $100,000 per QALY gained. The outpatient treatment provider perspective resulted in a costeffectiveness ratio of $25,049 per QALY gained with a slightly lower (*85 %) chance of being accepted as cost effective, using a willingness-to-pay value of $100,000. The total net social costs were lower for BMT but did not differ significantly.
Buprenorphine-Naloxone Maintenance Therapy Versus Naltrexone
Ruger et al. [70] conducted a CEA of a randomized doubleblind placebo-controlled clinical trial in Malaysia, testing the effectiveness of BMT, relative to naltrexone, for treatment of heroin dependence. The study participants were detoxified heroin-dependent patients from an outpatient research clinic and detoxification programme. The primary outcomes tested were the days in treatment, maximum consecutive days of heroin abstinence, days to first heroin use and days to heroin relapse. The secondary outcome measures were treatment retention, injection drug use, illicit opiate use, the AIDS Risk Inventory total score, and the drug risk and sex risk subscores. The authors concluded that buprenorphine was likely cost effective, relative to naltrexone, from a societal standpoint, given that it was more effective for all primary outcomes and most secondary outcomes, with cost-effectiveness ratios below $50 (in 2004 USD) for the primary outcomes and $350, generally, for the secondary outcomes.
Naltrexone Versus No Naltrexone
Adi et al. [19] Because of the amount of variability in the costs and QALYs between groups, the probability of naltrexone being considered cost effective never exceeded 55 % at the NICE cost-effectiveness threshold of £30,000 per QALY gained. 
Cost
Implementation
Barnett et al. [71] conducted a retrospective cohort analysis of patients seeking treatment for an opioid use disorder in a US Department of Veterans Affairs opioid substitution programme. Individuals in opioid substitution programmes that were highly concordant with clinical practice guidelines for MMT were compared with those in less concordant programmes. Over the 12 months following their index treatment, individuals in highly concordant programmes incurred $3776 (in 2002 USD) more in treatment costs and $7590 more in total healthcare costs, on average, than individuals in less concordant programmes. However, clients in highly concordant programmes experienced a number of significantly better outcomes than those in less concordant programmes: group therapy sessions and individual therapy sessions (37 versus 13.1 and 17.5 versus 16.9, respectively); percentage of individuals who were abstinent from heroin in the 30 days prior to assessment at 6 months (69.1 versus 54.9 %) and at 12 months (72.8 versus 54.4 %); and preference-weighted health-related quality of life at 6 months (0.675 versus 0.609). With regard to time of abstinence, the estimated ICER for highly concordant programmes was $102 per opiate-free day, relative to less concordant programmes.
Bell et al. [36] assessed the cost effectiveness of observed versus unobserved dosing of BMT among Australian heroin users in a 3-month clinical trial. The costs primarily reflected those of the payer but also included patient travel costs. The authors did not find any significant differences between participants in the observed and unobserved cohorts with respect to days of heroin use, quality of life or psychological state; however, they did find that the mean cost of treating the observed cohort exceeded that of the unobserved cohort by $1477 (in 2005 AUD).
Diversion and Aftercare Programmes
Hayhurst et al. [25] developed a decision analytic model to assess the cost effectiveness of diversion and aftercare programmes, relative to no programme, among adult class A offenders in England who were using either opiates or crack. The analyses were performed from multiple UKrelevant perspectives. The high level of variance in costs and QALYs resulted in insignificant differences for each and uncertainty regarding the cost effectiveness of these programmes.
Discussion
Almost a third of the economic evaluation studies included in this paper focused on identifying potential direct healthcare cost offsets associated with treatment for opioid use disorders through a change in the types of services utilized. According to our assessment via the Drummond checklist [27] , and as can be seen in Table 2 , all but two of the studies in this category were average. Overall the findings from these articles indicate that in spite of the higher outpatient or prescription costs associated with therapy, pharmacotherapy for opioid use disorders is associated with lower total healthcare costs primarily because of lower utilization of high-cost services such as ED use and inpatient care. Other outcomes of interest included lower criminal justice-related costs associated with MMT [39] , lower costs associated with buprenorphine-naloxone film versus tablets [44, 45] and improved retention for high-dose versus low-dose buprenorphinenaloxone patients, with no significant increase in total direct healthcare costs [46] .
The remaining economic evaluation studies included in this paper assessed both the costs and benefits of pharmacotherapy for opioid use disorders. Of these 30 remaining studies, 40 % (n = 12) focused on MMT, relative to residential therapy or an outpatient non-pharmacological alternative; two others assessed MMT or BMT, relative to a non-pharmacological alternative. As shown in Table 4 , ten of these 14 studies were rated as good on the basis of our evaluation via the Drummond checklist [27] ; the remaining four studies were rated as average. Six of the 14 studies used QALYs gained as an outcome measure [48, 54, 56, [58] [59] [60] , and all six ICER point estimates indicated that MMT would be considered cost effective according to the traditional US threshold for defining a value of $50,000 per QALY gained, or the WHO's recommendations for assessing the ICER, relative to the country's GDP per capita [57] . Two additional studies calculated ICERs, using HIV infections averted as the measure of effectiveness [52, 53] , while a third estimated an ICER with abstinent years in the denominator [62] . While the results from these studies focusing on cost per clinical outcome appear promising for MMT, unfortunately there is not an established willingness-to-pay threshold by which cost effectiveness can be judged, as there is with cost per QALY gained. Basu et al. [51] performed a net monetary benefit analysis using self-reported robbery as the unit of effectiveness, while Schwartz et al. [50] used benefit-cost ratios to assess the relative value of MMT. The remaining studies evaluated costs and effects separately. The results from these studies were also favourable for MMT.
A number of studies compared MMT with other pharmacological therapies, including injectable heroin [64, 65] , BMT [21, 31, 32, 66, 67] and naltrexone [67] . As can be seen in Table 6 , all but one of these studies was rated as good. With regard to injectable heroin, Nosyk et al. [64] found that it dominated MMT, while Byford et al. [65] found that to be the case for oral methadone but found that injectable heroin was slightly less cost effective than injectable methadone. Of the papers comparing MMT and BMT, only one was based on an RCT [31] and only one used QALYs as an outcome measure [21] . Moreover, the results of the studies comparing MMT and BMT were mixed but generally favoured MMT. Connock et al. [21] found that both BMT and MMT were cost effective, relative to no pharmacotherapy, at £13,697 and £26,429 (in 2004 GBP), respectively, per QALY gained, but MMT dominated BMT. Jones et al. [31] found that abstinence rates were statistically similar for BMT and MMT, but MMT was less expensive. Maas et al. [66] found that MMT dominated BMT with regard to 6-month retention rates, but BMT was more effective in terms of detox rates, generating an ICER of £903 (in 2010-2011 GBP) per individual who stopped using illicit opiates. Geitona et al. [32] found that BMT was significantly less expensive than MMT, from the Greek National Health System's perspective, and was more effective with regard to participants completing therapy and deaths avoided. Finally, Jackson et al. [67] found that MMT dominated BMT with regard to costs from a state addiction treatment payer perspective and an outcome measure of opioid-free days.
BMT was also compared with no treatment [68] , detoxification [69] and naltrexone [67, 70] . As indicated in Table 6 , the quality of these studies was good. In general, the results from these studies favoured BMT. Schackman et al. [68] and Polsky et al. [69] both estimated cost-per-QALY point estimates that fell within the aforementioned range of acceptable US values for cost effectiveness [61] ; however, Schackman et al. found that the therapy had only a 64 % chance of being considered cost effective at a willingness-to-pay threshold of $100,000, while the estimates by Polsky et al. revealed an 86 % chance at the same threshold value. Jackson et al. [67] estimated an ICER of $72 (in *2014 USD) per opioid-free day, relative to MMT, and Ruger et al. [70] estimated ICER values below $50 for a host of primary outcomes, including abstinence; however, as mentioned above, we were unable to assess the general level of acceptance for the cost effectiveness of these estimates.
Regarding naltrexone, in addition to the studies mentioned above, Adi et al. [19] created a decision analytic model comparing naltrexone with standard treatment from an NHS/PSS perspective. The estimated ICER of £42,500 (in 2004 GBP) per QALY gained was slightly higher than the NICE cost-effectiveness threshold of £30,000 per QALY gained. Moreover, the probability of naltrexone being considered cost effective at this threshold never exceeded 55 %.
Two studies assessed the cost effectiveness of CM as an add-on to treatment as usual for patients with a stimulant or opioid use disorder [33] , or a stimulant, alcohol or opioid use disorder [34] . Both studies used the longest duration of abstinence and the number of negative urine specimens as effectiveness measures, finding ICERs below $212 per week of abstinence and $156 per negative urine specimen. Once again, we were unable to assess these values relative to an established range of acceptable values.
One treatment strategy that has received little attention in terms of cost effectiveness is that of simply offering opioid use disorder therapy-that is, it may be that the availability of different modalities of treatment brings more people into treatment itself, which may be a cost-effective strategy. As mentioned in Sect. 1, only about 10 % of individuals with an opioid use disorder receive therapy [2] ; however, the majority of the cost-effectiveness studies have compared alternative therapies, as opposed to evaluating treatment versus no treatment.
Regarding implementation strategies, the findings by Bell et al. [36] indicated that unobserved dosing of BMT is more advantageous than observed dosing, as it was found to be less expensive, with no significant differences in days of heroin use, quality of life or psychological state. Barnett et al. [71] found that MMT programmes that were highly concordant with clinical practice guidelines were more expensive, on average, than less concordant programmes, but they were more effective with regard to therapy sessions completed, abstinence and preference-weighted health-related quality-of-life scores.
Finally, Hayhurst et al. [25] estimated the cost effectiveness of drug diversion and aftercare programmes for criminal justice-involved opiate-or crack-using individuals in the UK, via a decision analytic model. However, because of the level of variance around costs and QALYs, the authors concluded that there was not enough evidence to make a determination with regard to cost effectiveness.
Limitations
There were some important limitations associated with the studies included in this review that not only limited the findings of particular studies but also made it difficult to generate objective comparisons between studies. First, there was a wide range of study designs. Only 8 (19 %) of the economic evaluation studies included in this review were conducted for an RCT. Almost 42 % (n = 18) of the economic evaluation studies we reviewed were a retrospective cohort analysis, and 33 % (n = 14) were model based (e.g. decision analytic models). The quasi-experimental and model-based designs limited the ability of the researchers to make causal inferences [72, 73] , thereby limiting the validity of the economic outcomes as well. Second, there was a great deal of variability in the outcomes of interest. For example, many studies focused primarily on changes in healthcare utilization and the associated costs, with little to no attention on the effectiveness of the programmes in terms of whether the participants were made 'better off'. Among those studies that did incorporate effectiveness measures, many were clinical in nature. One problem with clinical outcomes is that they fail to capture many of the consequences associated with opioid misuse, such as changes in quality of life. A second problem with these types of outcomes, as mentioned above, is that a generally accepted range of cost-effectiveness threshold values has not been established, as it has with QALYs [49, 61] . The Panel on Cost Effectiveness in Health and Medicine [74] has recommended the QALY as the primary effectiveness outcome measure for economic evaluation studies, as it allows for comparisons across diseases and interventions. Finally, of those studies that did incorporate QALYs, the inconsistency in the perspectives that were adopted for the evaluations limited their comparability.
Conclusion
In general, the MMT studies included in this review contributed to the strong existing evidence that MMT is an economically advantageous form of therapy for opioid use disorders. However, the literature comparing MMT with other opioid use disorder pharmacotherapies is still quite limited. Additional research is needed, as there is variation in research designs, perspectives and outcomes. The existing economic evaluation literature pertaining to BMT and naltrexone is also rather limited at this point, particularly for naltrexone. The results appeared promising for BMT, CM and the therapy implementation strategies that were reviewed, but the results were mixed for naltrexone. However, with the possible exception of MMT, a great deal more work is required in these areas before solid inferences regarding their relative economic value can be made. Additionally, more cost-effectiveness analyses assessing treatment versus no treatment are needed, given that only about 10 % of individuals with an opioid use disorder receive therapy [2] .
Author contributions Sean Murphy and Daniel Polsky were responsible for defining the scope of the study, generating the inclusion and exclusion criteria for the articles, and finalizing the list of articles to be included in the review. Sean Murphy wrote the first draft of the manuscript. Both authors approved the final manuscript.
Compliance with ethical standards
Sources of Financial Support No funding was received to support this review.
